Department of Endocrinology and Metabolism, Center of Reproductive Medicine, Peking University Third Hospital, Beijing, China.
Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, China.
JAMA. 2017 Dec 12;318(22):2190-2198. doi: 10.1001/jama.2017.18249.
Presence of thyroid autoantibodies in women with normal thyroid function is associated with increased risk of miscarriage. Whether levothyroxine treatment improves pregnancy outcomes among women undergoing in vitro fertilization and embryo transfer (IVF-ET) is unknown.
To determine the effect of levothyroxine on miscarriage among women undergoing IVF-ET who had normal thyroid function and tested positive for thyroid autoantibodies.
DESIGN, SETTING, AND PARTICIPANTS: An open-label, randomized clinical trial involving 600 women who tested positive for the antithyroperoxidase antibody and were being treated for infertility at Peking University Third Hospital from September 2012 to March 2017.
The intervention group (n = 300) received either a 25-μg/d or 50-μg/d dose of levothyroxine at study initiation that was titrated according to the level of thyroid-stimulating hormone during pregnancy. The women in the control group (n = 300) did not receive levothyroxine. All participants received the same IVF-ET and follow-up protocols.
The primary outcome was the miscarriage rate (pregnancy loss before 28 weeks of gestation, which was calculated among women who became pregnant). The secondary outcomes were clinical intrauterine pregnancy rate (fetal cardiac activity seen at sonography observation on the 30th day after the embryo transfer), and live-birth rate (at least 1 live birth after 28 weeks of gestation).
Among the 600 women (mean [SD] age, 31.6 [3.8] years) randomized in this trial, 567 women (94.5%) underwent IVF-ET and 565 (94.2%) completed the study. Miscarriage rates were 10.3% (11 of 107) in the intervention group and 10.6% (12 of 113) in the control group, with the absolute rate difference (RD) of -0.34% (95% CI, -8.65% to 8.12%) over the 4.5-year study period. Clinical intrauterine pregnancy rates were 35.7% (107 of 300) in the intervention group and 37.7% (113 of 300) in the control group, with an absolute RD of -2.00% (95% CI, -9.65% to 5.69%). Live-birth rates were 31.7% (95 of 300) in the intervention group and 32.3% (97 of 300) in the control group, with an absolute RD of -0.67% (95% CI, -8.09% to 6.77%).
Among women in China who had intact thyroid function and tested positive for antithyroperoxidase antibodies and were undergoing IVF-ET, treatment with levothyroxine, compared with no levothyroxine treatment, did not reduce miscarriage rates or increase live-birth rates.
Chinese Clinical Trial Registry: ChiCTR-TRC-13004097.
重要性:在甲状腺功能正常的女性中,存在甲状腺自身抗体与流产风险增加有关。在接受体外受精和胚胎移植(IVF-ET)的女性中,左旋甲状腺素治疗是否能改善妊娠结局尚不清楚。
目的:确定左旋甲状腺素对甲状腺功能正常且甲状腺过氧化物酶抗体检测阳性的接受 IVF-ET 的女性的流产率的影响。
设计、设置和参与者:这是一项开放标签、随机临床试验,纳入了 2012 年 9 月至 2017 年 3 月期间在北京大学生第三医院接受治疗不孕症且抗甲状腺过氧化物酶抗体检测阳性的 600 名女性。
干预措施:干预组(n=300)在研究开始时接受 25μg/d 或 50μg/d 的左旋甲状腺素剂量,根据妊娠期间促甲状腺激素水平进行滴定。对照组(n=300)未接受左旋甲状腺素治疗。所有参与者均接受相同的 IVF-ET 和随访方案。
主要结局和测量指标:主要结局是流产率(妊娠 28 周前的妊娠丢失率,在怀孕的女性中计算)。次要结局为临床宫内妊娠率(胚胎移植后第 30 天超声观察到的胎儿心脏活动)和活产率(至少有 1 例活产在 28 周后)。
结果:在这项试验中随机分配的 600 名女性(平均[标准差]年龄 31.6[3.8]岁)中,567 名(94.5%)接受了 IVF-ET,565 名(94.2%)完成了研究。干预组的流产率为 10.3%(11/107),对照组为 10.6%(12/113),4.5 年研究期间绝对差异率(RD)为-0.34%(95%置信区间,-8.65%至 8.12%)。干预组的临床宫内妊娠率为 35.7%(107/300),对照组为 37.7%(113/300),绝对 RD 为-2.00%(95%置信区间,-9.65%至 5.69%)。干预组的活产率为 31.7%(95/300),对照组为 32.3%(97/300),绝对 RD 为-0.67%(95%置信区间,-8.09%至 6.77%)。
结论和相关性:在中国甲状腺功能完整且抗甲状腺过氧化物酶抗体检测阳性且接受 IVF-ET 的女性中,与不接受左旋甲状腺素治疗相比,左旋甲状腺素治疗并未降低流产率或增加活产率。
试验注册:中国临床试验注册中心:ChiCTR-TRC-13004097。